Ashok Godavarthi

Dr. Ashok Godavarthi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
MPMartin Purpura
Martin Purpura
RJRalf Jäger
Ralf Jäger
AGAshok Godavarthi
Ashok Godavarthi
DBDhananjaya Bhaskarachar
Dhananjaya Bhaskarachar
GTGrant M. Tinsley
Grant M. Tinsley
Purpose: L-Ascorbic acid (vitamin C) is an essential water-soluble vitamin that plays an important role in various physiological functions, including immune health. The stability of vitamin C in the gastrointestinal tract its bioavailability is limited. This study aimed to investigate if a liposomal form of vitamin C can increase absorption compared to standard vitamin C. Methods: In a randomized, double-blind, placebo-controlled, crossover fashion, 19 males and 8 females (n = 27; 36.0 ± 5.1 years, 165.0 ± 6.9 cm, 70.6 ± 7.1 kg) ingested a single-dose of placebo (PLA), 500 mg vitamin C (VIT C), and 500 mg liposomal vitamin C (LV-VIT C, LipoVantage®, Specnova, LLC, Tyson Corner, VA, USA). Venous blood samples were collected 0, 0.5-, 1-, 1.5-, 2-, 3-, 4-, 6-, 8-, 12-, and 24-hours after ingestion and were analyzed for plasma and leukocyte vitamin C concentration. Results: VIT C and LV-VIT C demonstrated significantly greater Cmax and AUC0 − 24 in plasma and in leukocytes compared to placebo (p < 0.001). Additionally, LV-VIT C had significantly higher Cmax (plasma + 27%, leukocytes + 20%, p < 0.001) and AUC0 − 24 (plasma + 21%, leukocytes + 8%, p < 0.001) values as compared to VIT C. Conclusion: Liposomal formulation of vitamin C increases absorption into plasma and leukocytes. Trial Registration: Clinical Trials Registry - India (CTRI/2023/04/051789).

20 February 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
RJRalf Jäger
Ralf Jäger
MPMartin Purpura
Martin Purpura
SWShawn D. Wells
Shawn D. Wells
KLKylin Liao
Kylin Liao
AGAshok Godavarthi
Ashok Godavarthi
Paraxanthine is a natural dietary ingredient and the main metabolite of caffeine in humans. Compared to caffeine, paraxanthine exhibits lower toxicity, lesser anxiogenic properties, stronger locomotor activating effects, greater wake promoting properties, and stronger dopaminergic effects. The purpose of this study was to evaluate the potential beneficial effects of paraxanthine supplementation on muscle mass, strength, and endurance performance in comparison to the control and other ingredients commonly used by athletes: L-theanine, alpha-GPC, and taurine. Male Swiss Albino mice from five groups (n = 8 per group) were orally administered paraxanthine (20.5 mg/kg/day, human equivalence dose (HED) 100 mg), L-theanine (10.28 mg/kg/day, HED 50 mg), alpha-GPC (41.09 mg/kg/day, HED 200 mg), taurine (102.75 mg/kg/day, HED 500 mg), or control (carboxy methyl cellulose) for 4 weeks. Exercise performance was evaluated using forelimb grip strength and treadmill endurance exercise. All animals were subject to treadmill training for 60 min 5 days per week. Blood draws were utilized to analyze lipid profile, liver health, renal function, and nitric oxide levels. Paraxanthine significantly increased forelimb grip strength by 17% (p < 0.001), treadmill exercise performance by 39% (p < 0.001), gastrocnemius and soleus muscle mass by 14% and 41% respectively (both p < 0.001), and nitric oxide levels by 100% compared to control (p < 0.001), while reducing triglyceride (p < 0.001), total cholesterol (p < 0.001), LDL (p < 0.05), and increasing HDL (p < 0.001) compared to control, and compared to L-theanine, alpha-GPC, and taurine. Results from this initial investigation indicate that, when compared to the control, L-theanine, alpha-GPC, and taurine, paraxanthine is an effective ingredient for various aspects of sports performance and may enhance cardiovascular health.

2 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SMS. Mehkri
S. Mehkri
KDK. G. Dinesh
K. G. Dinesh
AGAshok Godavarthi
Ashok Godavarthi
Krathish BopannaKrathish Bopanna
Krathish Bopanna
Background: Lutein and zeaxanthin (LZ) are macular xanthophyll carotenoids with antioxidant and blue-light filtering properties, but their oral bioavailability is limited. Lipid-based delivery systems may enhance absorption. Methods: We compared four single-dose LZ delivery systems in male Sprague–Dawley rats: (G1) LZ in medium-chain triglyceride (MCT) oil; (G2) LZ in MCT + phosphatidylcholine (PC); (G3) LZ in MCT + phosphatidylserine (PS); (G4) LZ in liposomal powder. Following an overnight fast, each group (n = 6) received an oral gavage of the assigned formulation. Serial blood samples were collected up to 24 h post-dose. Plasma lutein + zeaxanthin concentrations were quantified by a validated LC–MS/MS method. Non-compartmental pharmacokinetic (PK) parameters were computed (Phoenix WinNonlin®), and one-way ANOVA was used to make inter-group comparisons on ln-transformed metrics with Dunnett’s post hoc tests. Results: The PS-complexed formulation (G3) yielded the highest LZ exposure (mean C_max 69.63 ± 0.78 ng/mL; AUC_0-t 620.23 ± 16.41 ng·h/mL), significantly exceeding the MCT oil control (G1: 52.54 ± 0.70 ng/mL; 494.51 ± 13.70 ng·h/mL; p < 0.001). The PC-enriched oil (G2) and liposomal powder (G4) also produced higher C_max and AUC than G1 (p < 0.01). No differences in elimination half-life (t1/2 ≈ eight h) were observed between formulations. Conclusions: Phospholipids, especially PS, substantially improved the systemic availability of lutein and zeaxanthin compared with MCT oil alone. PS-based lipid complexes appear particularly effective, supporting their use in ocular-health formulations to maximise xanthophyll bioavailability.

21 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MSMehkri S.
Mehkri S.
DGDinesh K. G.
Dinesh K. G.
AGAshok Godavarthi
Ashok Godavarthi
Krathish BopannaKrathish Bopanna
Krathish Bopanna
Background: Lutein and zeaxanthin (LZ) are macular xanthophyll carotenoids with antioxidant and blue-light filtering properties, but their oral bioavailability is limited. Lipid-based delivery systems may enhance absorption. Methods: We compared four single-dose LZ delivery systems in male Sprague–Dawley rats: (G1) LZ in medium-chain triglyceride (MCT) oil; (G2) LZ in MCT + phosphatidylcholine (PC); (G3) LZ in MCT + phosphatidylserine (PS); (G4) LZ in liposomal powder. Following an overnight fast, each group (n = 6) received an oral gavage of the assigned formulation. Serial blood samples were collected up to 24 h post-dose. Plasma lutein + zeaxanthin concentrations were quantified by a validated LC–MS/MS method. Non-compartmental pharmacokinetic (PK) parameters were computed (Phoenix WinNonlin®), and one-way ANOVA was used to make inter-group comparisons on ln-transformed metrics with Dunnett’s post hoc tests. Results: The PS-complexed formulation (G3) yielded the highest LZ exposure (mean C_max 69.63 ± 0.78 ng/mL; AUC_0-t 620.23 ± 16.41 ng·h/mL), significantly exceeding the MCT oil control (G1: 52.54 ± 0.70 ng/mL; 494.51 ± 13.70 ng·h/mL; p < 0.001). The PC-enriched oil (G2) and liposomal powder (G4) also produced higher C_max and AUC than G1 (p < 0.01). No differences in elimination half-life (t1/2 ≈ 8 h) were observed between formulations. Conclusions: Phospholipids, especially with PS, substantially improve lutein and zeaxanthin systemic availability versus MCT oil alone. PS-based lipid complexes appear particularly effective, supporting their use in ocular-health formulations to maximise xanthophyll bioavailability.

9 July 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
RJRalf Jäger
Ralf Jäger
HLHendrik Luesch
Hendrik Luesch
MPMartin Purpura
Martin Purpura
AGAshok Godavarthi
Ashok Godavarthi
SBSebastian T. Balcombe
Sebastian T. Balcombe
EVEcaterina Vasenina
Ecaterina Vasenina
Background: Ulva lactuca (sea lettuce) is a green macroalgae rich in sulfated polysaccharides (ulvans), polyphenols, and pigments with documented antioxidant and anti-inflammatory activity in preclinical models. Translational human data remain limited. Methods: Twenty healthy adults (20–35 years; BMI 18.5–30 kg/m2) were enrolled in a single-center, randomized, double-blind, placebo-controlled, parallel-group trial (CTRI/2025/11/097278) and assigned 1:1 to receive 300 mg of an U. lactuca extract or matched placebo once daily for 28 days. Antioxidant biomarkers (GSH, MDA, catalase, GPx-1, thioredoxin) and inflammatory biomarkers (CRP, IL-6, IL-1β, IL-11, PPAR-γ) were measured at Day 0 and Day 28. Safety was assessed throughout. Results: Eighteen of 20 participants completed the study. Compared with placebo, U. lactuca produced significant within-group improvements at Day 28 in GSH (+4.04 ng/mL), GPx-1 (+67.8 µU/mL), and catalase (+32.4 kU/L) and reductions in MDA (−6.08 nmol/mL) and thioredoxin (−1.48 ng/mL); inflammatory markers CRP (−0.91 mg/L), IL-6 (−2.97 pg/mL), IL-11 (−4.28 ± 1.88 ng/mL) and IL-1β (−8.87 pg/mL) decreased and PPAR-γ increased. Conclusions: In this short-duration pilot trial, daily supplementation with 300 mg of an U. lactuca extract was well tolerated and modulated systemic oxidative-stress and low-grade inflammatory biomarkers in healthy adults. Larger and longer studies in populations with elevated oxidative stress are warranted.

23 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SMS. Mehkri
S. Mehkri
KDK.G. Dinesh
K.G. Dinesh
AGAshok Godavarthi
Ashok Godavarthi
Krathish BopannaKrathish Bopanna
Krathish Bopanna
Background: Lutein and zeaxanthin (LZ) support macular function, but oral absorption is limited by intestinal solubilization and uptake; phospholipid environments may improve micellization and enterocyte transport. Objective: To evaluate whether an anionic phosphatidylserine (PS) matrix enhances single-dose LZ exposure compared to phosphatidylcholine (PC), a reconstituted liposomal powder, and medium-chain triglyceride (MCT) oil in rats. Methods: Male Sprague–Dawley rats (n=6 per group) received oral gavage of dose-matched lutein (10 mg/kg) in four matrices (MCT, MCT+PC, MCT+PS, liposome); serial plasma samples (0–24 h) were analysed using validated LC–MS/MS (calibration 5–250 ng/mL). Noncompartmental pharmacokinetics were calculated; group differences in Cmax and AUC₀–t was evaluated via one-way ANOVA with Dunnett contrasts versus MCT. Results: LZ exposure followed the order PS > PC ≈ liposome > MCT. Cmax (ng/mL, mean ± SD): 52.54 ± 0.70 (MCT), 60.45 ± 1.24 (PC), 69.63 ± 0.78 (PS), 62.39 ± 1.12 (liposome). AUC₀–t (ng·h/mL): 494.51 ± 13.70 (MCT), 596.37 ± 30.29 (PC), 620.23 ± 16.41 (PS), 536.70 ± 18.42 (liposome). Dunnett vs MCT: PS p<0.001; PC and liposome p<0.01. T_max was approximately 2 hours for PS/PC versus about 3 hours for MCT/liposome; half-life was similar (~7.7–8.3 hours). Conclusions: Anionic PS oils increase LZ exposure and bioavailability more effectively than PC or liposomal powder at equal doses, without altering elimination.